The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

Global Narcolepsy Treatment market to Grow at 5.1% CAGR, Reaching USD 8,718.3 Million by 2034. Key Drivers Include Advanced Drugs, Devices, & Growing Awareness. NEWARK, DE, UNITED STATES ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Narcolepsy Treatment Market Narcolepsy Treatment Global Narcolepsy Treatment Market to Grow at 5.1% CAGR, Reaching USD 8,718.3 Million by 2034. Key Drivers Include Advanced Drugs, Devices, & Gro ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

E-2086 is under clinical development by Eisai and currently in Phase I for Narcolepsy. According to GlobalData, Phase I drugs for Narcolepsy have an 80% phase transition success rate (PTSR) indication ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) has earned a consensus rating of “Buy” from the seven ratings ...

Researchers from the University of Edinburgh and King’s College London believe the findings offer new insight into the ...

Jazz Pharmaceuticals plc recently disclosed its financial update and corporate overview at the J.P. Morgan Healthcare ...

Speaking at the JP Morgan Healthcare Conference 2025 yesterday (14 January), Cozadd said: “We’ve got some really exciting ...

The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy. -- LUMRYZ is the only FDA-approved once ...